David J. Schlanger Sells 2,597 Shares of Progyny, Inc. (NASDAQ:PGNY) Stock

Progyny, Inc. (NASDAQ:PGNY) Chairman David J. Schlanger sold 2,597 shares of the business’s stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $37.65, for a total transaction of $97,777.05. Following the completion of the transaction, the chairman now directly owns 86,312 shares of the company’s stock, valued at approximately $3,249,646.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Progyny Stock Up 2.6 %

Shares of PGNY traded up $0.95 during trading hours on Wednesday, reaching $37.99. 884,702 shares of the company traded hands, compared to its average volume of 815,893. The stock has a market capitalization of $3.67 billion, a P/E ratio of 59.74, a P/E/G ratio of 1.53 and a beta of 1.48. Progyny, Inc. has a 12-month low of $29.44 and a 12-month high of $44.95. The business has a fifty day moving average price of $37.93 and a 200-day moving average price of $35.59.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings data on Tuesday, February 27th. The company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.04. The firm had revenue of $269.94 million for the quarter, compared to analyst estimates of $274.08 million. Progyny had a net margin of 5.70% and a return on equity of 12.64%. The business’s quarterly revenue was up 26.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.03 earnings per share. As a group, research analysts predict that Progyny, Inc. will post 0.7 EPS for the current fiscal year.

Analyst Ratings Changes

PGNY has been the subject of a number of recent research reports. Leerink Partnrs reissued an “outperform” rating on shares of Progyny in a research note on Monday, February 26th. Barclays began coverage on shares of Progyny in a report on Wednesday, January 3rd. They issued an “overweight” rating and a $48.00 price target on the stock. Truist Financial cut their price target on shares of Progyny from $47.00 to $46.00 and set a “buy” rating on the stock in a report on Wednesday, February 28th. KeyCorp cut their price target on shares of Progyny from $45.00 to $43.00 and set an “overweight” rating on the stock in a report on Wednesday, February 28th. Finally, SVB Leerink began coverage on shares of Progyny in a report on Monday, February 26th. They issued an “outperform” rating and a $49.00 price target on the stock. Ten research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Progyny currently has a consensus rating of “Buy” and an average price target of $48.30.

Institutional Investors Weigh In On Progyny

Large investors have recently made changes to their positions in the stock. Gotham Asset Management LLC purchased a new stake in Progyny in the third quarter valued at $1,116,000. Northern Trust Corp raised its position in shares of Progyny by 1.3% in the third quarter. Northern Trust Corp now owns 1,166,806 shares of the company’s stock worth $39,695,000 after acquiring an additional 15,208 shares during the period. Invesco Ltd. raised its position in shares of Progyny by 67.0% in the third quarter. Invesco Ltd. now owns 888,427 shares of the company’s stock worth $30,224,000 after acquiring an additional 356,529 shares during the period. Deutsche Bank AG raised its position in shares of Progyny by 12.7% in the third quarter. Deutsche Bank AG now owns 42,029 shares of the company’s stock worth $1,430,000 after acquiring an additional 4,738 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Progyny by 7.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 630,648 shares of the company’s stock worth $21,455,000 after acquiring an additional 46,144 shares during the period. 94.93% of the stock is owned by hedge funds and other institutional investors.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.